Research and Development
An increasing number of vitamin K and menaquinone-7 scientific studies now substantiate present use. However, still more studies are necessary in bone and cardiovascular health -- as well as in new interesting areas where vitamin K2 may be important. This implies that further research is relevant and needed. Through a long-term agreement since 2006, NattoPharma has been in a close R&D collaboration with VitaK BV, University in Maastricht, the Netherlands. To strengthen our research NattoPharma also signed in 2013 a new and long-term research agreement with the Cardiovascular Research November Institute Maastricht, (CARIM), University of Maastricht. These agreements provide NattoPharma with the option to study mechanisms of action of vitamin K2 and to further evaluate the impact of Vitamin K2 on human health.
These R&D agreements and contacts with other outstanding medical institutions enable Nattopharma to explore and strengthen NattoPharma’s present recommendations and future use of MenaQ7 products. We are proud and excited to be part of and to stimulate the Vitamin K2 research in biochemical and clinical settings.
Dr. Cees Vermeer – one of the world leading experts on Vitamin K2
Professor Dr. Cees Vermeer, studied biochemistry at the University of Leiden, where he defended in 1973 his thesis entitled "The role of the initiation factor IF3 in the initiation of protein synthesis in Escherichia coli". After a two-year post-doctoral position at the Central Lab of the Dutch Red Cross Blood transfusion Center in Amsterdam, Vermeer was appointed in 1975 as Associate Professor of Biochemistry at the newly formed Maastricht University, where he founded his renowned Division on Vitamin K Research. Vermeer discovered the pivotal importance of vitamin K2 for bone and cardiovascular health and the major diagnostic importance of Matrix Gla-Protein (MGP) as a biomarker for cardiovascular disease and mortality. He invented the MGP technology by which circulating MGP can be quantified and used to estimate cardiovascular disease risk and arterial calcification.
Professor Vermeer belongs to the world’s top-2½ % of scientists, received an Honorary Doctorate (in 2001) at the Iuliu Hatieganu University of Medicine and Pharmacy in Cluj Napoca, Romania, is a Visiting Professor at the American University and has been a temporary advisor of the World Health Organization. Read more on Wikipedia
For futher information, please contact:
Anne B. Vik
SVP R&D and Regulatory Affairs